Stocks of major Indian pharmaceutical companies witnessed a decline on Friday amidst rising concerns over U.S. trade policies, specifically the implementation of 100% tariffs on branded and patented drug imports. Despite these tariffs posing minimal risk to Indian firms, whose primary exports to the U.S. consist of generic drugs, market responses reflected broader anxiety.
According to Sudarshan Jain, an official from the Indian Pharmaceutical Alliance, the anticipated effects on India’s drug exporters are expected to be limited. “The likely impact will be pretty minimal,” Jain stated, underscoring that generic drugs form the bulk of Indian pharmaceutical exports, which are less affected by such tariffs.
However, stocks from prominent companies including Sun Pharmaceutical and Divi’s Laboratories fell by 2.5% and 3.5%, respectively, contributing to a dip in the Nifty Pharma Index, which also saw a decline exceeding 2%. This downturn raises questions about investor sentiment amid turbulent trade relations with the U.S.
Ayush Abhijeet, from White Oak Capital Partners, indicated that the unease among investors may be unwarranted in terms of direct impact on earnings. “There has been a ratcheting of challenges to the Indian economy,” Abhijeet noted, pointing to a series of escalating tariffs and recent changes to H-1B visa fees. The initial 25% tariffs imposed by the U.S. in August increased to 50% following India’s purchase of Russian oil, which has added to the tension, with notable voices in the U.S. administration emphasizing the linkage to geopolitical strife.
Sectors such as textiles, gems, and jewelry have seen a more pronounced effect from these tariffs. Yet, Abhijeet emphasized that the foundation of the Indian economy—largely dependent on private consumption—will likely mitigate the overall impact of these levies. The recent announcement of a one-time visa fee of $100,000 for new H-1B applications significantly raised concerns, disproportionately affecting Indian professionals seeking opportunities in the U.S.
The rapid succession of these announcements has left investors apprehensive, with fears of additional escalations in trade tensions. Gyanendra Tripathi from risk advisory firm BDO Partners suggested that these tariff increases could be strategic moves by the U.S. aimed at leveraging negotiations for a more favorable trade agreement with India.
Abhijeet remained somewhat optimistic about the pharmaceutical sector, citing India’s existing competitive advantages in generic medicines. He asserted that, even in the face of potential tariffs on generic pharmaceuticals, he would maintain a level of confidence. “Generic pharma exporters are competitive and have few substitutes,” he remarked, suggesting that any tariffs would likely be absorbed by the end consumers rather than the exporters.
As the situation evolves, the Indian pharmaceutical industry will be pivotal in assessing its strategies while navigating the complexities of international trade relations.
